MSH2 and cancer: MSH2 ectopically expressed on the surface of tumour cells has been identified as a ligand for the human Vγ9Vδ2 TCR (39, 41, 42) Our study demonstrated that the killing of HPV+ and cancer organoid cells by BrHPP-activated γδ T cells was reduced in the presence of anti-MSH2 antibody, supporting the hypothesis that the increased levels of MSH2 contribute to sensitizing of HPV+ and cancer organoid cells to cytotoxicity mediated by γδ T cells.